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Introduction
Despite the benefits of pharmacological and non-
pharmacological treatments of symptoms in patients 
with multiple sclerosis (MS), there is a need for better 
control of these symptoms.
Hippotherapy as a complementary treatment can be 
defined as one-patient-one-horse physiotherapy treat-
ment with and on the horse. The primary goals of hip-
potherapy are regulating muscle tone (reduction in 
spasticity) and breathing, strengthening the torso 
muscles, improving balance control and coordination, 
as well as gait. In addition, hippotherapy promotes 
social communication in the patients’ lives and 
strengthens their self-esteem.1
There have been reports on a beneficial effect of 
hippotherapy on symptoms of MS since 1978.2 Until 
now, only one randomized controlled study with 18 
MS patients indicated evidence of the effectiveness of 
hippotherapy. Frevel and Mäurer3 compared an 
Internet-based home training program with hippo-
therapy for 12 weeks. While there was no difference 
in static and dynamic balance between groups after 
the intervention, pre–post improvement was statisti-
cally significant in both groups. A marked improve-
ment in fatigue and quality of life was also shown in 
the group receiving hippotherapy.
The hippotherapy for patients with multiple sclerosis 
(MS-HIPPO) trial is primarily based on the results of 
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Abstract
Background: Evidence-based complementary treatment options for multiple sclerosis (MS) are limited.
Objective: To investigate the effect of hippotherapy plus standard care versus standard care alone in MS 
patients.
Methods: A total of 70 adults with MS were recruited in five German centers and randomly allocated to 
the intervention group (12 weeks of hippotherapy) or the control group. Primary outcome was the change 
in the Berg Balance Scale (BBS) after 12 weeks, and further outcome measures included fatigue, pain, 
quality of life, and spasticity.
Results: Covariance analysis of the primary endpoint resulted in a mean difference in BBS change of 
2.33 (95% confidence interval (CI): 0.03–4.63, p = 0.047) between intervention (n = 32) and control 
(n = 38) groups. Benefit on BBS was largest for the subgroup with an Expanded Disability Status Scale 
(EDSS) ⩾ 5 (5.1, p = 0.001). Fatigue (−6.8, p = 0.02) and spasticity (−0.9, p = 0.03) improved in the inter-
vention group. The mean difference in change between groups was 12.0 (p < 0.001) in physical health 
score and 14.4 (p < 0.001) in mental health score of Multiple Sclerosis Quality of Life-54 (MSQoL-54).
Conclusion: Hippotherapy plus standard care, while below the threshold of a minimal clinically important 
difference, significantly improved balance and also fatigue, spasticity, and quality of life in MS patients.
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two monocentric pilot studies4,5 carried out by the 
Zentrum für Therapeutisches Reiten Johannisberg 
e.V., in cooperation with partners in the current trial 
consortium. Patients in the pilot study by Sager et al. 
(one-arm trial, 16 patients) showed an average 
improvement of 5.6 points on the Berg Balance Scale 
(BBS) by week 12. The pilot study by Schneider et al. 
(randomized crossover trial, 12 patients) showed an 
average improvement of 6.5 points on BBS after 
6 weeks of hippotherapy.
A randomized controlled trial is presented to evaluate 
whether hippotherapy plus standard care is superior to 
standard care alone in terms of balance function and 
further relevant outcomes in patients with MS.
Patients and methods
Trial design
MS-HIPPO was a prospective, randomized, exam-
iner-blinded, multicenter, comparative trial with an 
allocation of 1:1 to the two groups: hippotherapy plus 
standard care compared to standard care alone (as 
prior to the study). The intervention lasted for 
12 weeks. A study outline, including details on rand-
omization, inclusion and exclusion criteria, interven-
tional and control treatment, data management, 
statistical analysis, and sample size calculation, was 
provided in the MS-HIPPO study protocol.6 
Information required by the CONSORT (Consolidated 
Standards of Reporting Trials) guideline7 can be also 
found in the online appendix. The study was con-
ducted at five sites in Germany, all of which have hip-
potherapy experience as stipulated by the rules of the 
German Consortium for Therapeutic Riding.8 The 
principles of good clinical practice (GCP, ICH E6) 
and data protection laws were applied. The study was 
approved by the respective ethical committees of the 
participating sites and registered with the German 
Trial Registry (DRKS00005289).
Patients
MS patients older than 18 years who had a confirmed 
MS with spasticity of the lower limbs and an 
Expanded Disability Status Scale (EDSS)9 score 
between 4 and 6.5 were eligible for inclusion. Patients 
who had received hippotherapy within the last 
12 months, a body weight over 90 kg, no balance 
while sitting, and acute exacerbation during the 
4-week period before start of the therapy were 
excluded. A planned start of treatment with new anti-
spastic drugs or other medications that may have an 
influence on the assessed outcomes also resulted in 
exclusion. Prior to randomization, written informed 
consent was obtained from each patient.
Procedures
Eligible patients were randomized to one of the two 
groups using sealed opaque envelopes on the basis of 
a computer-generated randomization list. Allocation 
concealment was assured using permuted blocks of 
varying length.
Patients of the intervention group received hippother-
apy (as defined by the regulations for hippotherapy of 
the Deutsches Kuratorium für Therapeutisches Reiten 
e.V. (DKThR))8 once a week for 12 weeks as an add-
on therapy to their standard care, which remained 
unchanged. Patients in the control group continued 
their previous therapy. Over the study period, sympto-
matic drug treatment, immunotherapy, and physio-
therapy were kept unchanged in both groups.
Examinations and questionnaires were completed 
prior to the first hippotherapy session (baseline), after 
6–7 weeks (interim assessment) and after 12 weeks 
(final assessment). Physiotherapists who assessed the 
endpoints in a separate room were blinded and explic-
itly trained not to question patients or hippotherapists. 
Patients were individually instructed to keep confi-
dentiality of their allocation group.
Adverse events (AEs) were documented in the respec-
tive questionnaire forms as well as on the AE/serious 
adverse event (SAE) form by each center’s head hip-
potherapist, physiotherapist, or the study physician. 
SAEs were immediately communicated according to 
GCP. In the study centers, monitoring was undertaken 
by the Clinical Trials Centre Cologne (CTCC).
Outcomes
The primary endpoint was the change in the BBS10–13 
(difference from BBS baseline to week 12). Secondary 
endpoints were changes from baseline in fatigue 
(Fatigue Severity Scale (FSS)),14,15 health-related 
quality of life (Multiple Sclerosis Quality of Life-54 
(MSQoL-54)),16 pain (Visual Analogue Scale 
(VAS)),17,18 and spasticity (Numeric Rating Scale 
(NRS)).19
Sample size
In line with previous studies, it was decided that the 
smallest difference needed was an improvement of 6 
points in the BBS at 12 weeks. Calculations indicated 
that to demonstrate a BBS improvement of this size, a 
V Vermöhlen, P Schiller et al.
journals.sagepub.com/home/msj 1377
sample size of 64 (2 × 32) would be required (α = 5%, 
power = 80%). Assuming a dropout rate of 10%, a 
total of 70 patients (2 × 35) needed to be randomized. 
For simplicity reasons, the calculation was based on 
Student’s t test (standard deviation (SD): 8.3, 
Student’s t test, type 1 error rate: 5%, two-sided; 
assumptions based on results of two pilot studies4,5 as 
described in the trial protocol by Wollenweber et al.6).
Statistical analysis
Analyses were based on the modified intention-to-
treat set (modified ITT). This set encompasses all ran-
domized patients with valid baseline assessment. The 
primary endpoint change of BBS from baseline to 
12 weeks was calculated using an analysis of covari-
ance (ANCOVA) with the fixed effects group, center, 
age, gender, EDSS classification, and baseline BBS 
(type 2 sums of squares). Missing values were imputed 
through the last observation carried forward (LOCF) 
value. Moreover, a mixed-model repeated-measures 
(MMRM) analysis was done using non-imputed data 
with the fixed effects group, center, time, group by 
time, age, gender, EDSS classification, and baseline 
BBS (type 3 sums of squares, ARH1 covariance struc-
ture on time). For both approaches the focus of statisti-
cal inference was on the difference in marginal means 
for the change from baseline to 12 weeks. In a sensi-
tivity analysis, the per-protocol (PP) set including all 
the patients who were treated according to the protocol 
over the entire study period (i.e. for whom no major 
protocol deviations were documented) was used.
Analysis of secondary endpoints was descriptive. In 
addition, an ANCOVA analogous to the primary end-
point analysis was performed. Safety data, that is, 
AEs, were summarized by type, seriousness, inten-
sity, and relatedness. Preplanned subgroup analyses 
with respect to age and EDSS were carried out.6 
These analyses are essentially explorative, thus no 
correction for multiple testing was done. Calculations 
were performed with the software SPSS Statistics 22 
(IBM Corp., Armonk, NY, USA).
Results
Between September 2013 and March 2014, 70 
patients with stable MS (57 females, 13 males, median 
age: 51 years) were randomly assigned to intervention 
(32 patients) and control (38 patients). The interval 
between baseline and final examination was similar in 
both groups (median (interquartile range (IQR)); 
intervention: 12.6 (11.9–14.0); control: 13.1 (12.2–
14.2)). Information on the flow of patients and the 
numbers of analyses sets, including reasons of exclu-
sion, is summarized in Figure 1.
Demographic and baseline characteristics were bal-
anced (Table 1). In both groups, two-thirds of patients 
had an EDSS score of 5 or higher. Median duration of 
MS was 16.5 years (intervention) or 17.6 (control). 
About 96% of the patients received physiotherapy at 
the beginning of the study.
Primary endpoint: balance
Under study conditions and within 12 weeks, BBS 
improved in both groups. In the intervention group, 
the change in BBS from baseline to week 12 was 6.00 
points (95% CI: 4.2–7.8) versus 2.9 in the control 
group (95% CI: 1.5–4.4, derived from MMRM) 
(Table 2 and supplementary figure e-1). The mean dif-
ference in change between groups after 12 weeks was 
3.07 points (95% CI: 1.00–5.14, p = 0.004 (Table 2, 
MMRM)). Results of the preplanned ANCOVA were 
2.33 points (95% CI: 0.03–4.63, p = 0.047 (Table 2, 
LOCF ANCOVA)). The sensitivity analysis of the PP 
set revealed a difference in change between groups of 
4.61 (95% CI: 0.74–7.47, p = 0.002 (MMRM)).
Secondary endpoints: fatigue, spasticity, pain, 
and quality of life
In the intervention group, fatigue (FSS) and spasticity 
(NRS) improved from baseline to week 12 (FSS: 
−9.2, SD: 10.3; NRS: −1.7, SD: 2.2; supplementary 
table e-1), and in the control group, they hardly 
changed (FSS: −0.9, SD: 8.4; NRS: −0.6, SD: 1.8). 
The mean difference in change between groups was 
−6.8 (95% CI: −11.0 to −2.6, p = 0.002) for FSS and 
−0.9 (95% CI: −1.9 to −0.1, p = 0.031) for NRS. From 
baseline to week 12, individual pain perception, as 
measured via VAS, improved in both groups (inter-
vention: −7.4, SD: 16.8; control: −1.3, SD: 28.0; 
mean difference in change between groups: −3.1 
(−13.4 to 7.3), p = 0.555; it should be noted that the 
values were highly variable at the beginning and over 
the “study period”, supplementary table e-1).
The 54 MSQoL-54 items were summarized in the two 
subscales: mental health and physical health score. 
After 12 weeks, a significant effect in favor of the 
intervention group could be seen in both subscales. 
The mean difference in change between groups was 
12.0 (95% CI: 6.2–17.7, p < 0.001) in the physical 
health scale and 14.4 (95% CI: 7.5–21.3, p < 0.001) in 
the mental health scale (supplementary table e-1).
Subgroup analyses
Within 12 weeks, patients with EDSS < 5 at baseline 
experienced a similar change in BBS in both 
groups. In patients with an EDSS ⩾ 5 who received 
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hippotherapy, the BBS increased more markedly 
than in the control group (mean difference in 
change between groups: 5.1 points, 95% CI: 2.3–7.9, 
p = 0.001; Figure 2). In terms of secondary endpoints 
(with the exception of VAS), the subgroup of 
patients with EDSS ⩾ 5 who received the interven-
tion also showed a marked improvement as com-
pared to the control group (supplementary figures 
e-2 and e-3).
Safety
In 28 patients, a total of 49 AEs occurred over 
12 weeks (intervention: 22 AEs in 13 patients, con-
trol: 27 AEs in 15 patients, supplementary table e-2, 
separated by subgroups in supplementary table e-3). 
In the intervention group, one patient fell off the 
therapy horse but was able to continue therapy. Three 
further AEs could have been related to the participa-
tion in the study: In the control group, one patient had 
a fractured leg, while in the intervention group, two 
patients experienced the beginning of an MS relapse 
accompanied by painful muscle contractions.
In all, 3 of the 49 AEs were classified as being SAEs 
due to the necessary hospitalization (intervention: 1 
SAE (MS relapse), control: 2 SAEs (MS relapse and 
infection)).
There was no discernible relationship between the 
hospitalization and participation in the study.
Figure 1. Trial profile.
aEvents occurred after randomization, but before initial test; discovered after randomization.
V Vermöhlen, P Schiller et al.
journals.sagepub.com/home/msj 1379
Discussion
This study provides class I evidence that weekly hip-
potherapy plus standard care in comparison with 
standard care alone may improve balance function 
after 12 weeks.
The balance as measured by BBS improved in both 
groups, but to a significantly different degree. For 
patients in the intervention group receiving hippo-
therapy, the increase was 6.4 points (SD: 5.4) on 
average versus 3.1 points (SD: 5.1) in the control 
group under ongoing standard care. The preplanned 
ANCOVA of the modified ITT set detected a mean 
difference of 2.33 points (95% CI: 0.03–4.63, 
p = 0.047) between groups. Applying an MMRM 
analysis taking into account the intermediate assess-
ment confirmed the results.
Furthermore, a positive effect on quality of life and 
other MS-specific symptoms such as fatigue and 
Table 1. Baseline characteristics by assigned treatment.a
Intervention 
(hippotherapy, n = 30)
Control 
(n = 37)
Total  
(n = 67)
Median age (IQR) (years) 50 (45–53) 51 (47–56) 51 (46–55)
Sex
 Female 27 (90%) 27 (73%) 54 (81%)
 Male 3 (10%) 10 (27%) 13 (19%)
EDSS at inclusion 5.4 (1.0) 5.3 (0.9) 5.4 (0.9)
 <5 10 (33%) 11 (30%) 21 (31%)
 ⩾5 20 (67%) 26 (70%) 46 (69%)
Weight (kg) 67 (10.3) 70.6 (9.9) 69.0 (10.2)
Median time from onset of MS to inclusion (IQR) (years) 16.5 (11–20) 17.6 (11–27) 17.3 (11–23)
Physiotherapy (in accordance with the Regulations 
Governing the Prescription of Remedies)
29 (97%) 35 (95%) 64 (96%)
IQR: interquartile range.
aData are n (%) or mean (standard deviation (SD)) unless stated otherwise.
Table 2. Results for primary endpoint Berg Balance Scalea.
Baseline Week 6 Week 12 Difference between 
groups at 12 weeksb
LOCF ANCOVA 2.33 (0.03–4.63), p = 0.047
Mean (SD) Control (n = 37) 42.1 (10.9) 44.9 (9.8) 45.1 (10.9)  
Intervention (n = 30) 40.6 (11.5) 45.4 (9.3) 47.0 (8.7)  
Change Control (n = 37) 0 2.9 (4.7) 3.1 (5.1)  
Mean (SD) Intervention (n = 30) 0 4.8 (5.1) 6.4 (5.4)  
MMRM 3.07 (1.00–5.14), p = 0.004
EMM (95% CI) Control 0 2.5 (1.9–4.0) 2.9 (1.5–4.4)  
Intervention 0 4.3 (2.5–6.1) 6.0 (4.2–7.8)  
LOCF: last observation carried forward; ANCOVA: analysis of covariance; MMRM: mixed-model repeated-measures;  
EMM: estimated marginal mean; CI: confidence interval.
aData are mean (SD) or mean (95% CI).
bDifference between groups in change of Berg Balance Scale from baseline to 12 weeks derived from ANCOVA or MMRM.
Figure 2. Subgroup analyses of the change in Berg 
Balance Scale (BBS) after 12 weeks. Results are shown as 
difference between groups in change of BBS (mean, 95% 
CI; ANCOVA models of LOCF data).
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spasticity could be found. With all findings pointing 
in the direction of the intervention, we interpret the 
results as an indication for an overall benefit for the 
patients.
In order to understand whether the results have a rel-
evant effect on patients’ daily lives, they need to be 
interpreted in light of the minimal clinically impor-
tant difference. In a validation study, Stevenson20 
pointed out that a minimum detectable change score 
of ±6 BBS points “is necessary to be 90% confident 
of genuine change.” In a systematic review based on 
11 studies and 668 subjects, Downs et al.21 con-
cluded that there was “little specific guidance as to 
how confident one can be that a real change in 
balance has occurred between tests across time for 
individual patients.” They inferred that a change 
between 3 and 7 should be interpreted as a real 
change in balance for baseline scores of between 20 
and 56. In our trial, participants had baseline values 
around 41 points (Table 2). Beauchamp et al.22 stated 
that “anchor-based estimates of the MCID ranged 
from 3.5 to 7.1.” Lord et al.23 set 6 points on the BBS 
as the minimal clinically important difference for 
people with MS.
We therefore think that the change of 4.8 after 6 weeks 
and of 6.4 points after 12 weeks for the intervention 
group reflect a relevant change. We are aware that the 
difference of 3.07 points between the intervention and 
control group after 12 weeks as result of the MMRM 
analysis does not reach the threshold of a minimal 
clinically important difference. In addition, we 
observed significant effects on the secondary out-
comes of spasticity, fatigue, and quality of life. 
Especially on the results for quality of life, we assume 
that the improvement on the BBS is noticeable by 
patients in their daily activities. However, this may be 
an association and we cannot be sure about a causal 
relationship. The PP analysis detected a difference of 
4.57 points (1.32–7.82) (p = 0.007) between the two 
groups. This finding suggests that a hippotherapeutic 
regimen which follows the protocol may have a clini-
cally relevant positive effect. With a difference of 5.1 
points in change on BBS between groups, the sub-
group of patients with EDSS ⩾ 5 strongly benefitted 
from hippotherapy (Figure 2).
Secondary endpoints were chosen as they represent 
common general symptoms in MS as confirmed by 
clinicians.24–26 Furthermore, institutions which per-
form health technology assessments and deliver 
guidance for decision-making on reimbursement of 
therapeutic regimens strongly advocate the inclusion 
of direct patient-relevant outcomes including quality 
of life.
Positive effects could be found for all but one second-
ary endpoint. The minimum clinically important dif-
ferences of 1.5 and 2.5 points for the MSQoL-54 
physical and mental scales were surpassed by far.27 
Although we admit that there was an effect of positive 
expectation in the hippotherapy group, the effect with 
10 points and more is beyond a positive expectation. 
FSS and NRS improvements point to a positive effect 
for the intervention group. When using a sum score of 
36 as the cutoff for the presence of severe fatigue,14 
the proportion of patients with no severe fatigue 
increased from baseline to week 12 from 10% to 33% 
in the intervention group and from 14% to 19% in the 
control group. The effect on fatigue may be not causal 
but could be attributed to an altered perception of 
fatigue based on a better quality of life. These find-
ings are in accordance with a recent Cochrane 
review.28 According to 36 trials, exercise therapy may 
reduce fatigue in patients with MS. These results 
could not only be observed for endurance training but 
also for mixed or other training (e.g. yoga). At base-
line, pain as measured by VAS was lower in the inter-
vention group than in the control group, but similar 
after 12 weeks. This finding is in contrast to the other 
results of the trial. We assume that low initial pain 
scores and a high variance may explain these results. 
This is in accordance with Sager et al.,5 who found a 
reduction in the perception of pain with a 6-week hip-
potherapy and a high variance.
Throughout the study, pharmacotherapy was reported 
by the patients themselves and thus underlies the 
constraints of patient-reported data (supplementary 
table e-4). Drug treatment was stable in both groups 
(93% of the hippotherapy group reported no changes 
and 84% of the control group, supplementary table 
e-5). Yet, some data are missing, especially in the 
control group. Patients with a confirmed MS with 
spasticity of the lower limbs were eligible for inclu-
sion. Yet, spasticity was not quantified.
The results of this first randomized controlled multi-
center trial in the field of hippotherapy for MS patients 
indicate the positive effect of this therapy on balance 
and other relevant functions. We demonstrated that 
for complementary approaches, trials following GCP 
guidelines can be undertaken in settings that are not 
familiar with research. Hence, for the benefit of 
patients, we encourage health professionals and inde-
pendent foundations to be more proactive regarding 
research in non-pharmacological interventions. We 
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hope that with the necessary funding, future trials will 
be undertaken to extend the study period and to pro-
long the follow-up.
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